Teva Pharmaceutical Industries Ltd. ADR (TEVA) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q3 26	$0.11	$0.02	-81.8%	—	—	—
Q2 26	$0.46	$0.53	+15.2%	—	—	—
Q1 26	$0.67	$0.78	+16.4%	—	—	—
Q4 25	$0.62	$0.66	+6.5%	—	—	—
Q3 25	$0.46	$0.52	+13.0%	—	—	—
Q2 25	$0.7	$0.71	+1.4%	—	—	—
Q1 25	$0.66	$0.69	+4.5%	—	—	—
Q4 24	$0.55	$0.61	+10.9%	—	—	—
Q3 24	$0.51	$0.48	-5.9%	—	—	—
Q2 24	$0.76	$1	+31.6%	—	—	—
Q1 24	$0.61	$0.6	-1.6%	—	—	—
Q4 23	$0.53	$0.56	+5.7%	—	—	—
Q3 23	$0.55	$0.4	-27.3%	—	—	—
Q2 23	$0.71	$0.71	0.0%	—	—	—
Q1 23	$0.62	$0.59	-4.8%	—	—	—
Q4 22	$0.56	$0.68	+21.4%	—	—	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$1.23	—	—	$17.3B	—
FY24	—	-$1.45	—	—	$16.5B	—
FY23	—	-$0.5	—	—	$15.8B	—
FY22	—	-$2.12	—	—	$14.9B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$21.9B	$21.9B	$18.3B	$16.9B	$16.7B	$15.9B	$14.9B	$15.8B	$16.5B	$17.3B
YoY change	+11.5%	-0.23%	-16.4%	-7.57%	-1.36%	-4.68%	-6.01%	+6.16%	+4.41%	+4.31%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	21.9B	21.9B	18.3B	16.9B	16.7B	15.9B	14.9B	15.8B	16.5B	17.3B
Cost of revenue	10.3B	11.2B	10B	9.4B	8.9B	8.3B	8B	8.2B	8.5B	8.3B
Gross profit	11.7B	10.6B	8.3B	7.5B	7.7B	7.6B	7B	7.6B	8.1B	8.9B
Gross margin	53.2%	48.6%	45.4%	44.6%	46.4%	47.8%	46.7%	48.2%	48.7%	51.8%
Research & development	2.1B	1.8B	1.2B	1B	997M	967M	838M	953M	998M	1B
Selling, general & administrative	5B	4.8B	4.2B	3.8B	3.7B	3.5B	3.4B	3.5B	3.7B	4B
Operating expenses	7B	6.6B	5.4B	4.8B	4.7B	4.5B	4.3B	4.5B	4.7B	5B
Operating income	4.6B	4B	2.9B	2.7B	3.1B	3.1B	2.7B	3.2B	3.4B	4B
Operating margin	21%	18.3%	15.7%	16.1%	18.4%	19.5%	18%	20.2%	20.3%	22.9%
Non-operating income, net	-3.2B	-21.5B	-4.5B	-3.1B	-6.5B	-1.5B	-4.9B	-2.7B	-3.6B	-1.7B
Pretax income	824M	-18.4B	-2.6B	-1.3B	-4.4B	658M	-3.2B	-624M	-1.3B	1.2B
Income tax	521M	-1.9B	-195M	-278M	-168M	211M	-643M	-7M	676M	-180M
Net income	311M	-16.4B	-2.5B	-1B	-4.1B	456M	-2.5B	-615M	-2B	1.4B
Net margin	1.42%	-75.3%	-13.5%	-5.92%	-24.6%	2.87%	-16.7%	-3.88%	-11.8%	8.22%
EBITDA	6.1B	6B	4.7B	4.4B	4.5B	4.3B	3.9B	4.3B	4.4B	4.9B
EPS	0.07	-16.3	-2.35	-0.91	-3.64	0.38	-2.12	-0.5	-1.45	1.23
Diluted EPS	0.07	-16.3	-2.35	-0.91	-3.64	0.38	-2.12	-0.5	-1.45	1.21

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	3.9B	4.5B	3.8B	4.2B	4.3B	4.2B	3.9B	4.2B	4.5B	4.7B	4B	4.1B
Cost of revenue	2B	2B	2B	2.1B	2.2B	2.1B	2B	2.1B	2.2B	2.1B	2B	2B
Gross profit	1.9B	2.4B	1.8B	2B	2.1B	2.1B	1.9B	2.1B	2.3B	2.7B	2B	2.2B
Gross margin	48.1%	54.2%	46.4%	48.6%	49.6%	50.2%	48.2%	50.3%	51.4%	56.4%	49.5%	52%
Research & development	253M	227M	242M	269M	240M	247M	247M	244M	256M	267M	222M	970M
Selling, general & administrative	844M	902M	886M	939M	924M	952M	919M	959M	973M	1.1B	1B	1B
Operating expenses	1.1B	1.1B	1.1B	1.2B	1.2B	1.2B	1.2B	1.2B	1.2B	1.4B	1.2B	2B
Operating income	754M	1.2B	642M	816M	984M	922M	706M	899M	1.1B	1.3B	759M	149M
Operating margin	19.6%	27.9%	16.8%	19.6%	22.7%	21.8%	18.1%	21.5%	24%	26.9%	19.1%	3.6%
Non-operating income, net	-409M	-484M	-859M	-822M	-1B	-882M	-186M	-444M	-194M	-916M	-107M	-379M
Pretax income	64M	473M	-467M	-246M	-324M	-247M	294M	203M	646M	80M	437M	-455M
Income tax	-12M	41M	-52M	630M	69M	28M	74M	-78M	214M	-390M	67M	121M
Net income	77M	433M	-419M	-874M	-390M	-275M	220M	283M	434M	481M	369M	-575M
Net margin	2%	9.72%	-11%	-21%	-9%	-6.5%	5.65%	6.78%	9.69%	10.2%	9.27%	-13.9%
EBITDA	1B	1.5B	932M	1.1B	1.3B	1.1B	951M	1.1B	1.3B	1.6B	988M	379M
EPS	0.06	0.41	-0.12	-0.75	-0.39	-0.19	0.19	0.25	0.38	0.42	0.32	-0.49
Diluted EPS	0.06	0.41	-0.12	-0.75	-0.39	-0.19	0.18	0.24	0.37	0.41	0.31	-0.49

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	—	19.3B	15.7B	10.7B	10.6B	8.8B	10.1B	11.7B	24.9B	35.7B	45.3B
Enterprise value	—	50.8B	42.9B	36.1B	34.8B	30.1B	28.9B	28.6B	39.7B	49.3B	58.9B
Shares outstanding	955M	1B	1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	—	—	—	—	—	19.4	—	—	—	25.2	64.9
P/S	—	0.88	0.86	0.63	0.63	0.56	0.68	0.74	1.51	2.07	2.62
P/B	—	1.03	1	0.71	0.96	0.79	1.18	1.44	4.36	4.52	5.85
EV/EBITDA	—	8.42	9.08	8.23	7.65	6.94	7.39	6.7	9.06	10.1	13.8
EV/Sales	—	2.32	2.35	2.14	2.09	1.9	1.94	1.81	2.4	2.86	3.4
Earnings yield	—	—	—	—	—	5.17%	—	—	—	3.97%	1.54%
FCF yield	—	7.02%	11.4%	2.09%	6.04%	2.67%	10.3%	7.21%	3%	3.21%	4.9%
PEG	—	—	—	—	—	—	—	—	—	—	-0.22

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	53.2%	48.6%	45.4%	44.6%	46.4%	47.8%	46.7%	48.2%	48.7%	51.8%	52%
Operating margin	21%	18.3%	15.7%	16.1%	18.4%	19.5%	18%	20.2%	20.3%	22.9%	4.03%
Net margin	1.42%	-75.3%	-13.5%	-5.92%	-24.6%	2.87%	-16.7%	-3.88%	-11.8%	8.22%	4.08%
ROE	0.89%	-87.8%	-15.7%	-6.64%	-37.1%	4.06%	-29.1%	-7.57%	-34.2%	17.9%	9.69%
ROA	0.33%	-23.3%	-4.07%	-1.74%	-8.09%	0.96%	-5.68%	-1.41%	-4.98%	3.48%	5.13%
ROIC	2.42%	7.94%	6.68%	6.73%	8.67%	6.47%	9.83%	12.7%	16.4%	18.4%	15.2%
Return on tangible assets	-0.8%	76.5%	14.4%	6.81%	48.5%	-6.21%	65.8%	37.3%	-999.5%	119.6%	55.2%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	0.93	0.86	0.96	0.98	0.99	1.14	1.05	1.02	0.98	1.04	0.88
Quick ratio	0.66	0.58	0.63	0.66	0.65	0.79	0.72	0.69	0.75	0.8	0.67
Debt / equity	1.02	1.73	1.83	1.82	2.39	2.09	2.51	2.48	3.16	2.16	2.18
Debt / assets	0.38	0.46	0.48	0.48	0.52	0.49	0.49	0.46	0.46	0.42	0.42
Net debt / EBITDA	5.74	5.23	5.74	5.79	5.33	4.91	4.8	3.97	3.37	2.77	3.13
Interest coverage	2.51	-20	-1.82	-0.54	-3.89	1.74	-2.4	0.39	-0.28	2.34	1.79
Effective tax rate	63.2%	0%	0%	0%	0%	32.1%	0%	0%	0%	0%	1.69%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	22.9	21.5	17.9	15.5	15.2	14.4	13.4	14.2	14.6	15.1	15
EPS (basic)	0.07	-16.3	-2.35	-0.91	-3.64	0.38	-2.12	-0.5	-1.45	1.23	1.23
EPS (diluted)	0.07	-16.3	-2.35	-0.91	-3.64	0.38	-2.12	-0.5	-1.45	1.21	0.6
Book value per share	36.6	18.4	15.5	13.8	10.1	10.2	7.75	7.26	5.06	6.91	6.65
FCF per share	3.13	1.33	1.76	0.2	0.58	0.21	0.94	0.75	0.66	1	1.16
Cash per share	1.03	0.95	1.75	1.81	1.99	1.96	2.52	2.88	2.92	3.11	3.14
Capex per share	1.15	2.56	0.23	0.48	0.53	0.51	0.49	0.47	0.44	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	5.03%	11.9%	1.31%	3.11%	3.47%	3.54%	3.67%	3.32%	3.01%	—	—
Capex / operating cash flow	48.6%	-14.5%	-7.57%	-51.9%	-11.3%	510.9%	-63.2%	158.9%	-38.7%	—	—
Payout ratio	501%	-7.06%	-0.89%	-5.2%	—	—	—	—	—	—	0%
Dividend yield	—	6.03%	0.14%	0.49%	—	—	—	—	—	—	0.87%

Yield

0.87%

trailing twelve months

Frequency

Quarterly

Last dividend

$0.085

ex-dividend Nov 27, 2017

Payout ratio

of earnings

Dividend growth

0 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Nov 27, 2017	$0.085
Aug 25, 2017	$0.0722
Jun 1, 2017	$0.289

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$3.9B	$4.5B	$3.8B	$4.2B	$4.3B	$4.2B	$3.9B	$4.2B	$4.5B	$4.7B	$4B	$4.1B
YoY change	+7.09%	+14.8%	+4.29%	+7.4%	+12.5%	-5.12%	+1.89%	+0.29%	+3.44%	+11.4%	+2.31%	-0.81%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	988M	963M	1.8B	2B	2.2B	2.2B	2.8B	3.2B	3.3B	3.6B
Receivables	7.5B	7.1B	5.8B	5.7B	4.6B	4.5B	3.7B	3.4B	3.1B	3.7B
Inventory	5B	4.9B	4.7B	4.4B	4.4B	3.8B	3.8B	4B	3B	3.2B
Total current assets	17.2B	15.4B	13.8B	13.5B	13B	12.6B	12.1B	12.5B	12.6B	13.9B
Property, plant & equipment	4.7B	4.3B	4.2B	4.1B	4.1B	3.9B	3.7B	3.7B	3B	2.1B
Goodwill & intangibles	131.8B	92.1B	77.8B	72.2B	59.1B	55B	47.8B	45.1B	39.1B	39.6B
Total assets	93.1B	70.6B	60.7B	57.5B	50.6B	47.7B	44B	43.5B	39.3B	40.7B
Accounts payable	2.2B	2.1B	1.9B	1.7B	1.8B	1.7B	1.9B	2.6B	2.2B	2.5B
Short-term debt	3.3B	3.6B	2.2B	2.3B	3.2B	1.4B	2.1B	1.7B	1.8B	1.8B
Total current liabilities	18.5B	17.9B	14.3B	13.7B	13.2B	11B	11.5B	12.2B	12.8B	13.5B
Long-term debt	32.5B	28.8B	26.7B	25B	23.2B	22B	19.5B	18.5B	16.3B	15.3B
Total liabilities	58.1B	51.9B	44.9B	42.4B	39.6B	36.4B	35.4B	35.4B	33.6B	32.8B
Shareholders' equity	35B	18.7B	15.8B	15.1B	11.1B	11.2B	8.6B	8.1B	5.7B	7.9B
Total debt	35.8B	32.5B	28.9B	27.3B	26.4B	23.5B	21.6B	20.2B	18.1B	17.1B
Net debt	34.8B	31.5B	27.1B	25.4B	24.2B	21.3B	18.8B	16.9B	14.8B	13.5B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	2.2B	3.2B	3B	2.3B	3.3B	3.3B	1.7B	2.2B	2.2B	3.6B	3.7B	3.7B
Receivables	3.4B	3.4B	3.5B	3.8B	3.5B	3.1B	3.4B	3.6B	3.8B	3.7B	3.4B	3.5B
Inventory	4.1B	4B	3.9B	3.9B	4B	3B	3.2B	3.5B	3.3B	3.2B	3.2B	3.2B
Total current assets	11.4B	12.5B	12.3B	11.6B	12.3B	12.6B	11.5B	12.6B	12.7B	13.9B	13.7B	13.8B
Property, plant & equipment	6B	3.7B	6B	5.9B	6B	3B	5B	5.2B	5.2B	2.1B	4.3B	4.3B
Goodwill & intangibles	44.8B	45.1B	44.1B	42.7B	41.8B	39.1B	39.3B	40.2B	39.8B	39.6B	38.9B	38.6B
Total assets	42.1B	43.5B	42.8B	41.3B	41.8B	39.3B	38.4B	40.1B	39.9B	40.7B	40B	39.9B
Accounts payable	2.3B	2.6B	2.4B	2.4B	2.4B	2.2B	2.3B	2.5B	2.4B	2.5B	2.6B	2.7B
Short-term debt	1.5B	1.7B	3.1B	2.1B	2.6B	1.8B	421M	464M	24M	1.8B	2.6B	4.5B
Total current liabilities	11.4B	12.2B	13.8B	13B	13.8B	12.8B	11.2B	11.9B	11.5B	13.5B	13.5B	15.6B
Long-term debt	18.8B	18.5B	16.9B	16.8B	16.7B	16.3B	16.5B	17.1B	17B	15.3B	14.3B	12.4B
Total liabilities	34.6B	35.4B	35.2B	34.8B	35.4B	33.6B	32.1B	33.3B	32.6B	32.8B	31.8B	32.1B
Shareholders' equity	7.5B	8.1B	7.5B	6.6B	6.4B	5.7B	6.3B	6.8B	7.3B	7.9B	8.2B	7.8B
Total debt	20.3B	20.2B	19.9B	18.9B	19.3B	18.1B	16.9B	17.5B	17.1B	17.1B	16.9B	16.9B
Net debt	18B	16.9B	16.9B	16.7B	16B	14.8B	15.2B	15.4B	14.9B	13.5B	13.2B	13.2B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	311M	-16.4B	-2.5B	-1B	-4.1B	456M	-2.5B	-615M	-2B	1.4B
Depreciation & amortization	1.5B	2.1B	1.8B	1.7B	1.6B	1.3B	1.3B	1.2B	1.1B	1B
Stock-based compensation	124M	133M	155M	119M	129M	119M	124M	121M	123M	157M
Change in working capital	-116M	-1.6B	-1.8B	-896M	-2.2B	-1.7B	1.4B	-72M	-435M	-1.4B
Operating cash flow	2.3B	-18B	-3.2B	-1B	-5.1B	110M	-867M	331M	-1.3B	1.6B
Capital expenditure	1.1B	2.6B	239M	-525M	-578M	-562M	-548M	-526M	-498M	—
Investing cash flow	-35.7B	2.2B	131M	-132M	-542M	-125M	-484M	-509M	-499M	24M
Dividends paid	-1.6B	-1.2B	-22M	-52M	—	—	—	—	—	—
Share repurchases	0	0	—	—	—	—	—	—	—	—
Financing cash flow	25.2B	-5.8B	-3.6B	-2.5B	-2.4B	-3.4B	-1.5B	-2.6B	-1.8B	-2.2B
Net change in cash	-8.3B	-21.6B	-6.7B	-3.6B	-8.1B	-3.4B	-2.8B	-2.8B	-3.6B	-478M
Free cash flow	3B	1.4B	1.8B	223M	638M	236M	1B	842M	749M	1.1B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	77M	433M	-419M	-874M	-390M	-275M	220M	283M	434M	481M	369M	-575M
Depreciation & amortization	283M	266M	272M	259M	259M	269M	244M	251M	249M	260M	239M	241M
Stock-based compensation	31M	28M	28M	32M	29M	34M	34M	38M	34M	51M	43M	40M
Change in working capital	—	—	—	—	—	—	—	—	—	—	—	—
Operating cash flow	187M	800M	-306M	-416M	-152M	23M	518M	466M	369M	1.2B	-40M	411M
Capital expenditure	-149M	-119M	-124M	-97M	-148M	-129M	-127M	-96M	—	—	—	—
Investing cash flow	-178M	-120M	-151M	-139M	-71M	-140M	-121M	-100M	-3M	25M	43M	-698M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	—	—	—	—
Financing cash flow	-776M	-1.1B	-151M	-966M	0	-674M	-1.7B	6M	-453M	40M	13M	-1M
Net change in cash	-767M	-396M	-608M	-1.5B	-223M	-791M	-1.3B	372M	-87M	1.2B	16M	-288M
Free cash flow	-144M	1.1B	-248M	6M	545M	446M	-232M	131M	233M	1B	-208M	307M

Date	Ratio
Jul 1, 2004	2:1
Dec 6, 2002	2:1
Feb 23, 2000	2:1
Apr 14, 1993	2:1

Teva Pharmaceutical Industries Ltd. ADR Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement

Split history